6,678 trials
Hypertension
Primary: Median Dose Required to Increase the Systolic Blood Pressure (SBP) — 35; 43; 45 ng/kg/min
Plaque Psoriasis · Psoriatic Arthritis
Primary: Number of Participants Reporting Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) and AEs of Special Interests (AESIs) From Week 0 to Week 24…
Ptosis, Eyelid
Primary: Mean MRD1 After Phenylephrine — 2.08 mm
Benign Prostatic Hyperplasia · Lower Urinary Tract Symptoms
Primary: Change in Adapted International Prostate Symptom Score (IPSS) — 13.5; 12.1; 14.1; 9.2 score on a scale
Ileus · Gastrointestinal Dysfunction
Primary: Hospital Length of Stay — 5; 6 days
Constipation
Primary: Patient Assessment of Constipation Symptoms Questionnaire (PAC-SYM) Score — 1.1; 0.6 score
Cataract
Primary: Mean Anterior Chamber Cell/Flare Score — 1.06; 1.15 Units on a scale
Human Immunodeficiency Virus
Primary: Evidence of Toxicity. Toxicity Was Measured as Any Adverse Event; Nausea, Vomiting, Diarrhea. Elevated Liver Function Tests. — 4; 4 adverse events
Suicidal Ideation
Primary: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) — 13.69; 14.46; 8.27; 10.87 score on a scale
Pelvic Organ Prolapse · Perioperative/Postoperative Complications
Primary: Postoperative Opioid Use — 25; 20 MMEs
Adult Attention-Deficit Hyperactivity Disorder
Primary: ADHD-RS Change From Baseline to Endpoint — 11.85; 10.92 units on a scale — p=.779
HIV Infections · Renal Transplant Rejection
Primary: Number of Subjects With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies/ml — 19 Participants
Acute Heart Failure · Diuretics Drug Reactions
Primary: Mortality, Days in Hospital & Decongestion — 54.68; 44.16 % wins — p=0.357
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Complete Remission (CR) or Complete Remission With Incomplete Hematological Recovery (CRi) as Per Investigator's Assessment According to…
Upper Facial Lines
Primary: Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4…